William Blair analyst Matthew Phipps last night upgraded Genmab (GMAB) to Outperform from Market Perform without a price target. after the ...

CEO Jan van de Winkel added, “With EPKINLY moving from strength to strength and two wholly owned assets, rinatabart sesutecan and acasunlimab in Phase 3 development, we are confident in the ...

Still, he stressed that the strength of other programmes – including AbbVie-partnered Epkinly (epcoritamab) for non-Hodgkin lymphoma and phase 3 candidates Rina-S (rinatabart sesutecan ...

“With EPKINLY ® (epcoritamab) moving from strength to strength and two wholly owned assets, rinatabart sesutecan (Rina-S™) and acasunlimab in Phase 3 development, we are confident in the potential of ...

The company has several potential blockbuster treatments in the works, including Epkinly, Rina-S, and acasulimab. Genmab’s pipeline is robust, with a series of Phase III results expected to ...

getting past the highly anticipated J&J decision and expected share pullback now allows investors to focus on the company’s pipeline and potential blockbusters including Epkinly, Rina-S ...

The company has several potential blockbuster treatments in the works, including Epkinly, Rina-S, and acasulimab. Genmab’s pipeline is robust, with a series of Phase III results expected to start ...

Epkinly, for the treatment of relapsed or refractory diffuse large B-cell lymphoma; Welireg for the treatment of treatment of von Hippel-Lindau (VHL) disease; and, Yescarta for the treatment of ...

getting past the highly anticipated J&J decision and expected share pullback now allows investors to focus on the company’s pipeline and potential blockbusters including Epkinly, Rina-S, and ...

Vyalev in Parkinson’s disease and Epkinly in relapsed or refractory follicular lymphoma. The company also advanced several late-stage candidates and continued to build out its pipeline in 2024 ...